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Abstract
Background: Angelman syndrome (AS) is a rare neurodevelopmental disorder caused by the loss of functional
ubiquitin protein ligase E3A (UBE3A). In neurons, UBE3A expression is tightly regulated by a mechanism of
imprinting which suppresses the expression of the paternal UBE3A allele. Promising treatment strategies for AS are
directed at activating paternal UBE3A gene expression. However, for such strategies to be successful, it is important
to know when such a treatment should start, and how much UBE3A expression is needed for normal embryonic
brain development.
Methods: Using a conditional mouse model of AS, we further delineated the critical period for UBE3A expression
during early brain development. Ube3a gene expression was induced around the second week of gestation and
mouse phenotypes were assessed using a behavioral test battery. To investigate the requirements of embryonic
UBE3A expression, we made use of mice in which the paternal Ube3a allele was deleted.
Results: We observed a full behavioral rescue of the AS mouse model phenotypes when Ube3a gene reactivation
was induced around the start of the last week of mouse embryonic development. We found that full silencing of
the paternal Ube3a allele was not completed till the first week after birth but that deletion of the paternal Ube3a
allele had no significant effect on the assessed phenotypes.
Limitations: Direct translation to human is limited, as we do not precisely know how human and mouse brain
development aligns over gestational time. Moreover, many of the assessed phenotypes have limited translational
value, as the underlying brain regions involved in these tasks are largely unknown.
Conclusions: Our findings provide further important insights in the requirement of UBE3A expression during brain
development. We found that loss of up to 50% of UBE3A protein during prenatal mouse brain development does
not significantly impact the assessed mouse behavioral phenotypes. Together with previous findings, our results
indicate that the most critical function for mouse UBE3A lies in the early postnatal period between birth and P21.
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Background
Angelman syndrome (AS) is a neurodevelopmental dis-
order characterized by distinct features such as severe
intellectual disability, absence of speech, jerky move-
ments, hyperactivity, seizures, and EEG abnormalities
[1]. The genetic cause underlying AS became apparent
when a deletion of chromosome 15q11-q13 was identi-
fied on the maternally inherited allele [2, 3]. In contrast,
the deletion of the paternal 15q11-q13 locus causes
Prader-Willi syndrome (PWS), a disorder characterized
by obesity and hyperphagia. The discovery of neuronal
imprinting of chromosome 15q11-q13 explained the oc-
currence of two distinct disorders associated with the
same deletion [2]. Kishino and colleagues later identified
the ubiquitin protein ligase E3A (UBE3A) gene as the
causal gene for AS [4].
Imprinting of UBE3A is regulated by the expression of
an antisense RNA (UBE3A-ATS), which is expressed
from the paternally inherited chromosome in the brain
[5, 6]. No effective therapy is currently available for AS,
but the discovery of UBE3A-ATS-dependent silencing of
paternal UBE3A opened the door to pursue a treatment
that involves the reactivation of the paternal gene [7, 8].
Clinical trials that use antisense-oligonucleotides
(AONs/ASOs) to activate paternal UBE3A expression in
individuals with AS have recently been initiated and
offer a promising approach for treating AS.
For the clinical success of a paternal UBE3A gene re-
activation approach, it is essential to know if UBE3A is
critical for early brain development. If so, such a therapy
might have to be given at or even before birth [9]. To
address this question, we previously generated an indu-
cible Ube3a mouse line which contains a transcriptional
“STOP-cassette” flanked by LoxP sites (Ube3atm1Yelg;
from hereon called Ube3aLSL) allowing UBE3A expres-
sion after Cre-mediated deletion of the STOP cassette
[10]. By restoring UBE3A expression at different time
points, we observed that an early therapeutic interven-
tion is needed to rescue the majority of AS phenotypes
[10]. Specifically, we found that inducing UBE3A gene
expression around the first embryonic day of develop-
ment results in a full rescue of all phenotypes, whereas
inducing UBE3A gene expression at P21 only rescued
motor coordination. Neonatal gene reactivation resulted
in a limited behavioral rescue, but these results should
be interpreted with care, as we did not manage to get
full gene reinstatement in newborn mice. Hence, the
precise critical window for obtaining a full behavioral
rescue in a mouse model of AS remains undetermined.
It is important to realize that both Ube3a alleles are
expressed during early (prenatal) brain development as
paternal Ube3a gene silencing is not complete until the
first few days after birth [11]. If prenatal brain develop-
ment requires both copies of Ube3a to be active, Ube3a
gene reactivation after birth would have limited success.
To specifically address the importance of bi-allelic
UBE3A expression before birth, one can use mice in
which the paternal allele is mutated, whereas the mater-
nal gene is normally expressed. Mice lacking a functional
copy of maternal Ube3a (m−/p+; “AS” mice) exhibit a
number of robust phenotypes, including phenotypes that
are directly relevant to AS [10, 12–16], but very few
studies have investigated the effect of deleting the pater-
nal Ube3a allele. Paternal loss of Ube3a expression af-
fects the development of the cerebellum [12], but this
does not have an impact on the motor performance [12,
13, 17, 18]. These findings are in line with a study that
showed a limited role of the cerebellum in AS mice on
these tasks [19]. However, it has been reported that dele-
tion of both Ube3a alleles in mice affects licking behav-
ior in a different way compared to maternal Ube3a
deletion [17] which could suggest specific changes in
cerebellar function.
The aim of this study is to further delineate the re-
quirement of UBE3A expression during prenatal brain
development. To address this, we used two approaches.
First, we investigated a conditional mouse model of AS
in which maternal Ube3a expression is reactivated be-
fore the last week of mouse embryonic development.
Second, we investigated the importance of paternal
Ube3a expression during prenatal brain development.
Methods
Mouse breeding
We made use of Ube3aLSL (Ube3atm1Yelg; MGI:5704099)
mice as previously described [10]. These mice were
maintained in the 129S2 background (full name: 129S2/
SvPasCrl) by crossing male 129S2 Ube3am+/pLSL mice
with 129S2 females. For the behavioral experiments, we
used mice in the B6129S2F1 background, which were
generated as described below. To generate embryonic
reactivation of Ube3a at E12.5, 129S2 Ube3am+/pLSL fe-
male mice were crossed with Nestin-Cre-expressing
male mice (Tg(Nes-cre)1Kln; MGI:2176173) [20] in the
C57BL/6J background (Charles River Laboratories). This
breeding yielded 4 experimental groups in a B6129SF1
background: WT mice with and without Cre, and
Ube3amLSL/p+ mice with and without Cre.
To test the role of paternal Ube3a on behavioral out-
come measures, we made use of Ube3atm1Alb mice
(MGI:2181811 )[12] (Fig. 3a) and Ube3aE113X mutants
(Ube3atm2Yelg; MGI:5911277) [21] (Fig. 3b). Ube3atm1Alb
mice were maintained (> 40 generations) in the 129S2
background by crossing male Ube3am+/p− mice with fe-
male 129S2 wild-type mice. Ube3atm2Yelg mice were
maintained (> 20 generations) in the C57BL/6J (Charles
River) background by crossing male Ube3am+/pE113X
mice with female C57BL/6J wild-type mice. To generate
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mice lacking Ube3a on either the maternal or pater-
nal or both alleles, we crossed female Ube3atm1Alb
mice with male Ube3atm2Yelg mice. This breeding
yielded 4 experimental groups: WT mice, heterozy-
gous Ube3am+/p− mice, Ube3am−/p+ (AS) mice, and
homozygous Ube3am−/p− mice.
To test the contribution of both Ube3a alleles on
UBE3A expression, we made use of Ube3atm2Alb mice in
which UBE3A is fused to YFP (MGI:3771814) [22].
Ube3atm2Alb mice were maintained for > 20 generations in
C57BL/6J, by crossing male Ube3am+/pUbe3a-YFP mice with
female C57BL/6J wild-type mice. To generate mice ex-
pressing Ube3a-YFP on either the maternal or paternal al-
lele, we crossed female Ube3am+/pUbe3a-YFP mice with male
129S2 wild-type mice, or male Ube3am+/pUbe3a-YFP with fe-
male 129S2 wild-type mice.
Mouse husbandry
All mice were group-housed in a barrier facility, in indi-
vidually ventilated cages (IVC; 1145 T cages from Tech-
niplast). Mice were genotyped when they were 4–7 days
old, and re-genotyped at the completion of the experi-
ments. All animals were kept at 22 ± 20C with a 12-h
dark and light cycle, and provided with mouse chow
(801727CRM(P) from Special Dietary Service) and water
ad libitum. During behavioral testing, mice remained
group-housed, except during the nest building test and
subsequent forced swim test. Since we previously pub-
lished a small but significant effect of sex on the rotarod
and nest building test in a meta-analysis [14], we tried to
balance the groups as much as possible (See Additional
File, Table 1).
Behavioral test battery
All behavioral experiments were performed during the
light period of the light/dark cycle. Both male and fe-
male mice were used between 8 and 12 weeks of age.
Mice were acclimatized to the testing room for 30 min
before each behavioral performance. All behavioral test-
ing and scoring were performed by an experimenter
blind to genotype. Behavioral tests were precisely per-
formed as previously described [14] and as listed below:
Accelerating rotarod. Motor capabilities were tested by
placing the mice on the accelerating rotarod (4–40 rpm,
in 5 min; model 7650, Ugo Basile Biological Research
Apparatus, Varese, Italy). Mice were tested twice a day
with a 45–60-min inter-trial interval for 5 consecutive
days (same hour every day). For each day, the average
time spent on the rotarod was calculated, or the time
until the mouse made 3 consecutive wrappings/passive
rotations on the rotarod (latency in seconds). Maximum
duration of a trial was 5 min.
Reversed rotarod. Motor capabilities in the Ube3a pa-
ternal deficient line were tested by placing the mice on
the accelerating rotarod (4–40 rpm, in 5 min; modified
model 7650, Ugo Basile Biological Research Apparatus,
Varese, Italy) in such a way that they are walking back-
wards. Mice were tested twice a day with a 45–60-min
inter-trial interval for 5 consecutive days (same hour
every day). For each day, the average time spent on the
rotarod was calculated, or the time until the mouse
made 3 consecutive wrappings/passive rotations on the
rotarod (latency in seconds). Maximum duration of a
trial was 5 min.
Open Field test. In this test, which is useful to test
locomotor activity and anxiety, mice were individually
placed in a brightly lit 110-cm diameter circular open
field (25 lux in the middle of the arena) and allowed to
explore the space for 10 min. The total distance moved
by each mouse in the open arena was recorded by an in-
frared camera (Noldus® Wageningen, NL) connected to
the EthoVision® software (Noldus® Wageningen, NL),
and the outcome measure indicated as distance moved
in centimeters.
Marble burying test. Open makrolon (polycarbonate)
cages (50 × 26 × 18 cm) were provided with 4 cm of bed-
ding material (Lignocel® Hygenic Animal Bedding, JRS).
On top of the bedding material 20 blue glass marbles
were placed in an equidistant 5 × 4 grid and the animal
was placed in this cage for 30 min. The outcome meas-
ure is the number of buried marbles, which were scored
as buried when covered by more than 50% by bedding
material.
Nest Building test. Mice were single housed for a
period of 5 to 7 days before the start of the experiment.
Successively, the used nesting material was replaced with
around 11 grams (11 ± 1) of compressed extra-thick blot
filter paper (Bio-rad). The amount of the unused nesting
material was weighed and noted daily for 5 consecutive
days, each day at the same hour
Forced swim test. Mice were placed in a cylindrical
transparent tank (27 cm high and 18 cm in diameter),
filled with water (26 ± 1 °C) 15 cm deep for 6 min. The
outcome measure is the time in seconds in which the
mouse was immobile. The latency of immobility was
only assessed during the last 4 min of the test. The
mouse was considered to be immobile when it stopped
moving, making only movements necessary to keep its
head above water.
Western blot analysis
To assess UBE3A expression, brain tissues were dis-
sected and immediately stored in liquid nitrogen. The ly-
sates were made by homogenization in lysis buffer (10
mM Tris-HCl, pH 6.8, 2.5% SDS, 2 mM EDTA) and sup-
plemented with protease and phosphatase inhibitor
cocktails (Sigma-Aldrich). Twenty micrograms of pro-
tein lysate was loaded on 4–12% SDS-PAGE gel (Bio-
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Rad) and transferred on nitrocellulose membranes to be
then incubated with anti-UBE3A antibody (E8655
Sigma-Aldrich; 1:1000) and anti-actin antibody
(MAB1501R, Millipore; 1: 20,000). Membranes were
blocked in 4% TBS milk solution for 1 h at room
temperature and incubated at 4 °C overnight, rotating
end over end, with the primary antibody dissolved in 2%
TBS-T milk solution. The day after, membranes were
washed 3 times for 10 min with TBS-T and incubated
with the secondary antibody, a fluorophore-conjugated
goat anti-mouse antibody (IR Dye 800CW, Westburg; 1:
15,000), dissolved in 2% TBS-T milk solution for 1 h. At
the end of the incubation, membranes were washed 3
times for 10 min with TBS and the resulting blots were
analyzed and quantified using a LI-COR Odyssey Scan-
ner and Odyssey 3.0 software.
Immunofluorescent and immunohistochemical staining
Mice were sedated with 0.15 ml Nembutal (60 mg/kg),
transcardially perfused, and the brains were post-fixed
with 4% paraformaldehyde in sodium phosphate buffer
(PB) for 2 h. After incubation in 10% sucrose (in 0.1M
Phosphate buffer) overnight, brains were embedded in a
sucrose/gelatin mixture (10 and 12%, respectively). Brain
sections were cut on a microtome (SM2000R; Leica
Microsystems, Rijswijk, Netherlands) at a thickness of
40 μm. The brain sections were then washed in PBS and
incubated for 1 h in blocking buffer containing 10% nor-
mal horse serum (NHS) and 0.5% Triton X-100 in PBS.
Subsequently, sections were incubated for 48–72 h in 2%
NHS, 0.5% Triton X-100 diluted in PBS with primary
antibody (mouse anti-E6AP, clone 3E5 Sigma-Aldrich; 1:
750) and kept at 4 °C. For fluorescent stainings, sections
were washed with PBS and the secondary antibody was
added (anti-mouse Alexa 488, Jackson ImmunoResearch
Labs, 1:200 diluted) in PBS containing 2% NHS and
0.5% Triton X-100. After 1–2 h incubation of the sec-
ondary antibody at room temperature, sections were
washed in PB (0.05M), mounted on, and covered using
Mowiol (Sigma-Aldrich). Fluorescent images were ac-
quired using the LSM700 confocal microscope (Zeiss).
For DAB stainings, the secondary antibody (anti-mouse
HRP, P0447 Dako; 1:200) was detected by 3,3-diamino-
benzidine (DAB) as the chromogen, and DAB sections
were imaged using a Nanozoomer scanner.
Statistical analysis
All data were statistically analyzed using IBM SPSS soft-
ware, and P values < 0.05 were considered significant.
Statistical analysis was performed using univariate
ANOVA or 2 way-repeated measures ANOVA with
Bonferroni’s post hoc comparison. A Greenhouse-
Geisser correction was used in repeated ANOVAs when
the assumption of sphericity was not met.
For the Nestin-Cre experiments, a highly significant ef-
fect of genotype and highly significant interaction be-
tween presence and absence of Cre versus presence of
absence of Ube3amLSL was observed for the nest building
task, the marble burying test, and forced swim test (all p
< 0.005). In line with previous power calculations, we
did not have sufficient power to detect genotype differ-
ences for rotarod and open field when using four geno-
type groups [14]. To increase statistical power, we
combined the WT Cre+ and Cre− groups for subsequent
statistical analysis, including the Bonferroni tests, which
yielded a significant effect of genotype for rotarod. For
the open field task, no significant effect of genotype
could be observed.
Results
Characterization of the Nestin-CRE conditional AS mouse
model
Previously we generated the inducible Ube3aLSL line
containing a floxed transcriptional “STOP-cassette” en-
abling UBE3A expression upon Cre-mediated deletion
[10]. A partial rescue of behavioral phenotypes was ob-
served when UBE3A expression was induced at postnatal
day 1 (P1). However, since we achieved normal UBE3A
gene expression in only 30% of the cells, a failure to res-
cue certain behaviors could also be attributed to a failure
to induce gene expression in all cells. To further zoom
in on this critical period for UBE3A functioning, we in-
vestigated if reactivation of Ube3a around the onset of
the third week of mouse pregnancy would rescue AS
phenotypes, thereby further narrowing down the critical
window of UBE3A expression for full behavioral rescue.
We took advantage of the Nestin-Cre line, in which Cre
expression is under the control of the Nestin promoter
[20], and crossed this line with the Ube3aLSL line [10],
resulting in Ube3amLSL/Cre+ (Cre-positive) and
Ube3amLSL/Cre− (Cre-negative) control mice. Nestin is
an intermediate filament protein that is known as a
neural stem/progenitor cell marker [23–25]. Since the
Nestin promoter becomes active around E12.5 [26], we
estimated that sufficient Cre expression to mediate dele-
tion of the STOP cassette and to induce expression of
UBE3A protein at wild-type levels would be reached
around the start of the third week of mouse embryonic
brain development. Indeed, Western blot analysis of
brain UBE3A protein levels confirmed normal UBE3A
protein levels in Ube3amLSL/Cre+ mice at E15, whereas
no expression of maternal UBE3A expression was ob-
served in these mice at E9 (Fig. 1a, b). Consistent with
the expression profile of Nestin, immunohistochemical
and immunofluorescent stainings of adult Ube3amLSL/
Cre+ mice confirmed that UBE3A gene expression was
obtained throughout the brain (Fig. 1c, d).
Sonzogni et al. Molecular Autism           (2020) 11:70 Page 4 of 12
UBE3A gene reactivation around the third week of mouse
embryonic development prevents the manifestation of AS
phenotypes
After the biochemical validation of the new AS mouse
line, we subjected wild-type mice (with and without Cre),
Ube3amLSL/Cre+, and Ube3amLSL/Cre− control mice to a
well-characterized and robust behavioral testing battery
[10, 14]. Ube3amLSL/Cre− control mice showed a signifi-
cant deficit in all tasks except the open field task (p =
0.16) for which we previously showed that this is the
weakest phenotype and for which we calculated that a
sample size of 21 mice per group is required for sufficient
power (1 − β = 0.95) [14]. In contrast, Ube3amLSL/Cre+
mice, in which UBE3A expression was induced around
the start of the last week of mouse embryonic develop-
ment, were not significantly different from wild-type mice
on rotarod (WT vs Ube3amLSL/Cre+, p = 0.79), nest build-
ing (p value WT vs Ube3amLSL/Cre+ = 0.8), marble bury-
ing (WT vs Ube3amLSL/Cre+, p = 0.25), and the forced
swim test (WT vs U Ube3amLSL/Cre+, p = 0.65). This indi-
cates that activating the maternal Ube3a allele around the
onset of the last week of mouse embryonic development is
sufficient to prevent the development of these phenotypes
(Fig. 2b–e, Additional file 1: Table 1).
Fig. 1 Successful maternal Ube3a gene activation upon Nestin-Cre-mediated deletion of the transcriptional STOP cassette. a, b Western blot data
and UBE3A quantification from total lysates of E9 and E15 brains of Ube3amLSL+, Ube3amLSL/− mice, and WT littermates normalized to WT E15
levels. Bars depict mean ± SD (n = 2 per genotype, per time point). c, d DAB and immunofluorescent pictures of UBE3A expression in sections of
brains from adult wild-type, Ube3amLSL/Cre+ and Ube3amLSL/Cre− mice
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Assessing paternal Ube3a expression during brain
development
From the Western blot analysis of Fig. 1, it is clear that at
E9, approximately 50% of UBE3A is still present in
Ube3amLSL/Cre− mice. Given that the Ube3amLSL/Cre−
mice and Ube3amLSL/Cre+ mice show similar UBE3A
levels, and that the Nestin promoter is not yet active at
that time point, this protein must be derived from the pa-
ternal allele. Indeed, it has been shown that imprinting of
the paternal allele is not completed till the first week after
birth [11]. To investigate specifically the contribution of
the paternal Ube3a allele during early brain development,
we performed a Western blot on cortical lysates isolated
from WT and AS (Ube3am−/p+) mice at E14, E17, P1, P7,
P14, P21, and adult mice. These results showed that
UBE3A is entirely bi-allelically expressed at E14 (Fig. 3a),
and only after birth the paternal allele gets fully silenced.
Notably, UBE3A levels in wild-type mice remained rela-
tively constant throughout development, despite increased
silencing of the paternal allele. These results confirm
previous findings that genomic imprinting does not serve
to reduce the total amount of UBE3A [27].
Given that the total amount of UBE3A expression is
not affected upon paternal silencing, expression of the
maternal Ube3a allele must be increased during develop-
ment to compensate for the loss of paternal expression.
Likewise, there may be compensatory upregulation of
the paternal allele in the absence of maternal Ube3a ex-
pression. Hence, it is possible that the level of paternal
UBE3A expression as observed in AS (Ube3am−/p+) em-
bryos and pups (Fig. 3a) is increased as well. If such a
compensatory mechanism is in place, we would expect
that the total sum of UBE3A, as observed in Ube3am−/p+
plus Ube3am+/p− mice, exceeds the amount of UBE3A as
observed in wild-type mice. To test this, we crossed male
Ube3am+/p− mice (Ube3aE113X mutants) with female
wild-type mice, as well as female Ube3am+/p−
(Ube3aE113X mutants) with male wild-type mice and
quantified the amount of UBE3A protein in the mutant
progeny at E17. As shown in Fig. 3b, the total sum of
Fig. 2 Behavioral testing of Ube3amLSL/Nestin-Cre mice show a full rescue of most AS-like behavioral phenotypes. a Schematic representation of
Ube3a gene reactivation during mouse embryonic development around 2 weeks of gestation and time point of behavioral testing. b–e
Accelerating rotarod test, nest building test, marble burying test, and forced swim test in WT and Ube3amLSL mice (WT, n = 28; Ube3amLSL/Cre−, n
= 14; Ube3amLSL/Cre+, n = 12). A repeated measures ANOVA or univariate ANOVA was used for statistical comparison of genotypes. Asterisk
indicate significant effects of genotype: *P < 0.05; **P < 0.01; ***P < 0.001
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UBE3A protein produced in mice, in which the maternal
or paternal Ube3a gene is deleted (99%), is comparable
to the amount of UBE3A observed in wild-type mice.
Hence, loss of the maternal Ube3a allele, does not result
in compensatory upregulation of the paternal Ube3a
allele.
Finally, we directly quantified the expression of both
alleles within the same animals, by breeding mice in
which the maternal allele expresses UBE3A and the pa-
ternal allele expresses UBE3A-YFP [22]. However, the
values for UBE3A-YFP immunoreactivity are lower when
compared to the values obtained when endogenous
UBE3A is expressed from that same allele. Hence, we
calibrated the paternal UBE3A-YFP values obtained
from E17 pups, with the values obtained from E17 pups
in which UBE3A was expressed exclusively from the
Fig. 3 Silencing of the paternal Ube3a gene is not completed till after birth. a Total and paternal UBE3A expression during development. UBE3A
was quantified upon Western blot analysis of total cortical lysates isolated from WT and AS (Ube3am−/p+) mice at E14 (n = 8,5), E17 (n = 2,2), P1 (n
= 6,3), P7 (n = 5,5), P14 (n = 4,3), P21 (n = 3,2), and adult mice (n = 2). Note that despite silencing of the paternal allele (red bars), total UBE3A
levels remain rather constant (black bars), suggesting that the expression of the maternal allele increases at the same rate as the silencing of the
paternal allele. All values are normalized against UBE3A levels in adult WT mice. Error bars represent mean ± SEM. b Loss of maternal UBE3A
expression does not result in upregulation of paternal UBE3A expression. Note that the sum of UBE3A expression in Ube3am−/p+ and Ube3am+/p−
mice does not exceed 100%. UBE3A was quantified upon Western blot analysis of total lysates obtained from cortex isolated from WT (n = 5),
Ube3am−/p+ (n = 5), and Ube3am+/p− (n = 5) mice at E17. All values were normalized against UBE3A levels in WT mice. Error bars represent mean
± SEM. Absolute (c) and relative (d) expression levels of both alleles during development in Ube3am+/pUBE3A-YFP mice. c UBE3A and UBE3A-YFP
signals were determined upon Western blot analysis of total lysates of cortex of Ube3am+/pUBE3A-YFP mice at E17 (n = 3), P1 (n = 2), P4 (n = 3), P7
(n = 3), P14 (n = 3), and P21 (n = 2). To enable direct comparison of both alleles, UBE3A-YFP immunoreactivity values of E17 Ube3am+/pUBE3A-YFP
pups were calibrated against the UBE3A values of E17 Ube3am−/p+ pups of b. The relative contribution of each allele was subsequently
determined by calculating the contribution of each allele as percentage of both alleles for each time point (d). e Schematic representation of
UBE3A levels in WT, Ube3amLSL/Nestin-Cre, Ube3am+/p−, and Ube3am−/p+ mice, indicating that Ube3am+/p− mice can effectively be used as a UBE3A
reinstatement model in which UBE3A levels are restored to normal levels after birth. The data points for this figure are based on the Western
blots of b and a–d.
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paternal allele (as shown in Fig. 3b). The obtained re-
sults allow a direct comparison of both alleles during
development, and confirm that full paternal Ube3a si-
lencing is achieved in the first postnatal days of de-
velopment (Fig. 3c, d).
Contribution of paternal Ube3a expression to the
behavioral phenotypes
We have previously shown for different Ube3a mutants
that our behavioral testing battery is very sensitive to
mutations affecting maternal Ube3a gene expression [10,
14, 28, 29]. Given the observation that the paternal allele
is highly expressed throughout prenatal brain develop-
ment (Fig. 3a–d), we wondered whether loss of paternal
Ube3a expression (Ube3am+/p− mice) would also cause
behavioral phenotypes on these tests. In fact, given the
late onset of paternal silencing, Ube3am+/p− mice are
conceptually comparable to a Ube3a gene reinstatement
experiment in which we induce Ube3a gene activation
around birth (see Fig. 3e for a graphical representation
of this model).
Besides analyzing the effect of loss of paternal gene ex-
pression, we also wondered whether loss of both pater-
nal and maternal Ube3a expression (Ube3am−/p−) would
worsen the behavioral phenotype compared to mice in
which only the maternal Ube3a allele is deleted.
In order to disentangle the functional role of the ma-
ternal and paternal allele, we made use of two distinct
Ube3a mutants that both cause loss of Ube3a expres-
sion: the commonly used Ube3am−/p+ mice in which
exon 5 is deleted (Ube3atm1Alb; [12]) and the Ube3aE113X
mutant (Ube3atm2Yelg; [21]) which carries a premature
stop codon in exon 5. Both lines were shown to be simi-
larly affected in all tasks of the behavioral testing battery
[14]. Crossing these two lines with each other allowed us
to determine whether the paternal or maternal allele was
mutated in heterozygous offspring. This breeding yielded
4 experimental groups: WT mice, heterozygous
Ube3am+/p− mice, Ube3am−/p+ mice, and homozygous
Ube3am−/p− mice.
Immunofluorescent staining of brains derived from
adult mice of these 4 experimental groups shows that
the expression of UBE3A in mice lacking the paternal al-
lele (Ube3am+/p− mice) is comparable to wild-type mice
(Fig. 4a). In contrast, adult mice lacking maternally de-
rived UBE3A (Ube3am−/p+ mice) show very low levels of
UBE3A immunoreactivity, and even less staining was ob-
served in the double mutants in which both maternal
and paternal Ube3a alleles (Ube3am−/p− mice) are mu-
tated (Fig. 4a). This was further confirmed by Western
blot analysis of cortex, hippocampus, striatum, and cere-
bellum (Fig. 4b). In liver and lung, heterozygous
Ube3am+/p− and Ube3am−/p+ mice show comparable
UBE3A expression, approximately 50% compared to
wild-type levels. This confirms bi-allelic Ube3a expres-
sion outside the brain and, moreover, that both Ube3a
mutant lines similarly affect Ube3a gene expression.
The four experimental groups were then subjected to
the behavioral test battery as described above. However,
given the effect of paternal gene deletion on cerebellar
maturation [12], we used the more difficult reversal
rotarod task rather than the standard rotarod testing to
increase the sensitivity of this task. Ube3am−/p+ mice
lacking the maternal allele showed a significant pheno-
type on all tests compared to wild-type littermate con-
trol mice. (Fig. 5, Additional file 1: Table 1). Ube3am+/p−
mice lacking an active paternal Ube3a gene showed a
tendency to display reduced performance compared to
wild-type mice on all tests, but this never reached statis-
tical significance. Similarly, Ube3am−/p− mutants in
which both the maternal and paternal Ube3a allele were
deleted, showed a tendency to impaired performance
compared to Ube3am−/p+ mice lacking only the maternal
allele, but again this never reached statistical signifi-
cance. This suggests that lack of paternal gene expres-
sion throughout prenatal brain development does not
have a measurable effect on the phenotypes tested.
Discussion
The purpose of this study was to further delineate the
requirement of UBE3A expression during prenatal brain
development. In order to address this question, we took
advantage of a conditional mouse model of AS, in which
the maternal Ube3a allele is reactivated around the onset
of the third week of mouse embryonic development. In
addition, we investigated the importance of expressing
the paternal Ube3a allele during prenatal brain develop-
ment, especially in terms of its contribution to the AS
established phenotypes.
By reactivating Ube3a around the onset of the last
week of mouse embryonic development, we were able to
rescue all behavioral phenotypes in which AS mice were
affected. These findings further narrow down the previ-
ously identified critical window for therapeutic interven-
tion [10]. In our previous study [10], we identified a
critical window for Ube3a reinstatement that lies be-
tween E0-P21. In this study, early embryonic reinstate-
ment of Ube3a (E0) prevented AS phenotypes across
different behavioral domains from developing. In con-
trast, postnatal reinstatement (P0–P21) rescued only few
of the previously reported test battery phenotypes [10].
When we take our previous findings into account as well
[10], our newest results suggest that the critical window
for complete reversal of behavioral phenotypes can be
narrowed down from the period around birth to P21
(Fig. 5f). It is notable that this period coincides with the
period that UBE3A activity is controlled by PKA-
mediated phosphorylation in mice and that loss of this
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phosphorylation due to a UBE3A-p.T485A mutation re-
sults in ASD in human [30].
We showed that during mouse embryonic develop-
ment, UBE3A is expressed from both alleles. We found
that around E14, expression is still bi-allelic, and full si-
lencing of the paternal allele has not been achieved until
the first week after birth, which is in line with previous
findings [11]. We also observed that the total amount of
UBE3A expression during development is not affected
by paternal silencing, suggesting that there is a mechan-
ism that increases maternal UBE3A expression at a com-
parable rate as the loss of paternal UBE3A expression.
This observation is consistent with previous findings
[27]. In contrast, we observed that loss of maternal
UBE3A expression does not result in any compensatory
expression of the paternal allele.
To further investigate the requirements of embryonic
UBE3A expression levels, we made use of Ube3am+/p−
Fig. 4 UBE3A expression in WT, Ube3am+/p− mice, Ube3am−/p+ mice, and Ube3am−/p− mice. a Immunofluorescent staining of sections of cortex,
hippocampus, striatum, and cerebellum of brains isolated from adult WT, Ube3am+/p− mice, Ube3am−/p+ mice, and Ube3am−/p− mice. b Western
blotting and UBE3A quantification in peripheral (liver and lung) and non-peripheral (cortex, hippocampus, striatum, and cerebellum) areas. Error
bars represent mean ± SEM
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mice in which the paternal Ube3a allele was mutated. In
these mice, UBE3A protein levels were reduced to 50%
during the first 2 weeks of embryonic brain
development, and increased up to 80% of WT levels
around birth. Analysis of these mice showed a tendency
of decreased performance on all tests, but the effects
Fig. 5 Limited function of the Ube3a paternal allele in the development of AS-like behavioral phenotypes. a–e Accelerating rotarod, nest
building, open field, marble burying, and forced swim test in WT, Ube3am+/p−, Ube3am−/p+, and Ube3am−/p− mice (n = 15 per genotype). A
repeated measures ANOVA or univariate ANOVA was used for statistical comparison of genotypes. Asterisks indicate significant effects of
genotype, p < 0.001. Error bars represent mean ± SEM. f Schematic representation of several Ube3a lines used for studying the critical period,
which indicates that the critical window of rescuing behavioral deficits in AS mice by gene reinstatement lies around birth and P21. Each curve
depicts the level of UBE3A protein in WT, Ube3amLSL/Nestin-Cre, Ube3am+/p−, Ube3am−/p+, and Ube3am−/p− mice (this study) over time. In addition,
we included the previously published result of Ube3amLSL mice crossed with the inducible Cag-CreERT line in which gene reactivation was induced
by tamoxifen injection at P21 [10]. The presence of behavioral phenotypes has been indicated for each mouse line
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were small and did not reach statistical significance.
Hence, 50% of UBE3A protein is sufficient for normal
prenatal brain development. Moreover, these experi-
ments suggest that the critical period for UBE3A-
dependent brain development in mice is restricted to the
first few weeks after birth (Fig. 5f).
Limitations
Our study has two major limitations. The first limitation
is that we do not know how well the requirements for
UBE3A expression during mouse brain development
align with human brain development. The AS murine
model has been widely used in the biomedical AS field
to investigate potential therapeutic approaches, but des-
pite the similarities between mouse and human, mice
obviously have a much shorter lifespan compared to
humans and timing of brain development and systems
level functioning is very different. Several studies tried to
investigate how we can correlate the two species in
terms of brain development and function [31, 32]. When
we align major developmental milestones, such as time
to the weaning period or the age to attain puberty, 1 hu-
man year equals approximately 4 mouse days, and 57
mouse days, respectively [32]. A more elaborate com-
parison that includes brain anatomical milestones as well
as major behavioral milestones indicates that mouse P1
compares to early second trimester in human [31, 32].
But if we aim to draw a parallel in identifying the best
period for a behavioral rescue, it is particularly import-
ant to look at the critical periods underlying the devel-
opment of sensory pathways, language, and higher
cognitive functions [33, 34]. The best-understood critical
periods controlling specific attributes of primary sensory
modalities in animals are the representation of different
tones in the auditory cortex or left versus right eye in-
puts in the visual cortex [34]. For this last case, the crit-
ical period for acquiring binocular vision closes around
4 weeks of age in mice, while in humans it remains open
till 7 years of age [35]. Altogether, these studies indicate
that it remains highly uncertain how we can precisely
correlate the newly identified critical window to the hu-
man condition. But regardless of these limitations, our
study suggests that early postnatal intervention is likely
to be most successful to rescue AS related phenotypes
and that the UBE3A gene plays a critical role in perinatal
mouse brain development, but less so in adult mice [28].
The second limitation is that most of the behavioral
tests we used have limited clinical value. With the ex-
ception of the rotarod, we do not know what brain areas
are underlying the deficits in the open field test, marble
burying test, nest building test, and forced swim test.
These measures were selected because we have previ-
ously shown that they give robust phenotypes in differ-
ent lines of AS mice and different genetic backgrounds
[10, 14, 28, 29]. In addition we have previously calcu-
lated the power of these tests [14]. From that study, we
know that we were underpowered to see a significant ef-
fect in the open field, which was indeed the case for the
first set of experiments using the Ube3amLSL/p+/CRE+
mice.
A minor limitation of our study is that although we
did not find a statistically significant effect of paternal
Ube3a gene deletion, all tests showed a tendency in the
same direction. Hence, we cannot exclude a small effect,
meaning that for optimal embryonic mouse brain devel-
opment expression of both alleles is required. But never-
theless, our data implies that by losing 50% of protein
expression before birth, the effect on the mouse behav-
ioral phenotypes that we assessed is at best small.
Conclusion
Our findings provide further important information
about the requirements of Ube3a expression during
brain development. Taken together with our previous
studies [10, 28], our findings have further defined the
critical period for obtaining a full behavioral rescue by
Ube3a gene reinstatement strategies, and show that this
period lies just after birth and before P21 [10] in AS
mice (Fig. 5f). In addition, we show that loss of up to
50% of UBE3A protein during embryonic mouse brain
development does not significantly impact the assessed
mouse behavioral phenotypes.
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